Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Munsat, T. L.
Right arrow Articles by Jackson, I. M.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Munsat, T. L.
Right arrow Articles by Jackson, I. M.D.
NEUROLOGY 1987;37:597
© 1987 American Academy of Neurology

Pharrnacokinetics of intrathecal thyrotropin-releasing hormone

Theodore L. Munsat, MD, James Taft, PA-C and Ivor M.D. Jackson, MD

Neuromuscular Research Unit, Department of Neurology (Dr. Munsat and Mr. Taft) and Tufts-New England Medical Center, Boston, MA; and the Division of Endocrinology (Dr. Jackson), Brown University, Providence, RI.

An investigation of the efficacy of thyrotropin-releasing hormone in amyotrophic lateral sclerosis included study of the intrathecal pharmacokinetics of this neuropeptide. Its mean elimination half-life in CSF was 0.90 hours and was monoexponential. During a 2-hour infusion, 2.75% crossed the CSF/blood-brain barrier. Infusion for 12 months with an implanted pump in three patients at a rate of 3 mg/24 hr resulted in a mean CSF steady state of 2.88, 2.42, and 2.74 µg/ml, respectively. Pharmacokinetic data were similar at 6 and 12 months. This is an effective system with potential uses in the treatment of other degenerative diseases.

Address correspondence and reprint requests to Dr. Munsat, Department of Neurology, Tufts-New England Medical Center, 171 Harrison Avenue, Boston, MA 02111.

Supported by NIH grants GCRC #M01RR00054 and AM 34540, and a grant from the Muscular Dystrophy Association.

Received February 14, 1985. Accepted for publication in final form July 18, 1986.




This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
L. B. Marangell, M. S. George, A. M. Callahan, T. A. Ketter, P. J. Pazzaglia, T. A. L'Herrou, G. S. Leverich, and R. M. Post
Effects of Intrathecal Thyrotropin-Releasing Hormone (Protirelin) in Refractory Depressed Patients
Arch Gen Psychiatry, March 1, 1997; 54(3): 214 - 222.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.